$IVA

Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 30, 2026 - Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the potential proceeds for the Tranche C of the Debt Financing Transaction was mistakenly stated as €20 million. The correct figure is €55 million.

Inventiva (Euronext Paris and Nasdaq: IVA) reported preliminary 1H 2026 results. Cash and cash equivalents were €166.1 million at June 30, 2026, versus €99.3 million at Dec. 31, 2025. Net cash used in operating activities was (€48.7) million. R&D expenses were (€50.1) million. No revenues were recorded. The company expects funding into Q2 2027, or Q1 2028 with potential tranches.

Inventiva S.A. (NASDAQ:IVA) said July 9 it completed the final step of its June 2, 2026 EIB warrant restructuring. The company issued about 15.7 million new warrants to the European Investment Bank and canceled remaining legacy EIB warrants not repurchased. Inventiva said the change removes anti-dilution provisions and improves capital structure as it advances lanifibranor for MASH.

Inventiva (Euronext Paris and Nasdaq: IVA) said it completed its June 2, 2026 EIB warrant restructuring by issuing 15,677,573 new EIB warrants to the European Investment Bank at €0.01 each. The warrants can be exercised for shares at €0.01 and expire Jan. 4, 2036. Remaining legacy EIB warrants were surrendered and canceled.

Inventiva (Euronext Paris and Nasdaq: IVA) said it completed its EIB warrant restructuring, issuing 15.7 million new EIB warrants to the European Investment Bank and cancelling remaining legacy EIB warrants not repurchased. New warrants are priced and exercisable at €0.01, expire Jan. 4, 2036, and would equal about 6.5% of current share capital if exercised.

Inventiva (Euronext Paris/NASDAQ: IVA) reported results of its June 30, 2026 Combined Shareholders’ Meeting. Shareholders adopted all resolutions except the 31st, which would have authorized certain share capital increases for a company savings plan. The meeting approved the 2025 compensation policy for corporate officers. Total shares: 236,280,202; quorum: 71.874%.

Inventiva (Euronext Paris/Nasdaq: IVA) reported voting results from its Combined Shareholders’ General Meeting on June 30, 2026. Shareholders adopted all resolutions except the 31st, which would have authorized share capital increases for a company savings plan. The meeting also approved the 2025 compensation policy for corporate officers. Total shares with voting rights: 236,280,202; quorum: 71.874%.

Gide advised Inventiva, a biopharmaceutical company, on combined cross-border financing. According to Gide, Inventiva raised about $120m via an offering of American depositary shares in the U.S., and arranged new bond and convertible bond financing of €75m initially (up to €130m subject to conditions). The transactions also included a €50m repurchase of EIB warrants and full repayment of existing EIB debt. Cooley advised on U.S. law.

Claret Capital Partners will invest €43m in Inventiva (Euronext Paris and Nasdaq: IVA) as part of Inventiva’s €130m committed debt financing, with an additional uncommitted tranche of up to €20m, according to the companies. The funding supports Phase 3 development of lanifibranor for MASH; Inventiva expects NATiV3 top-line readout in Q4 2026.

Inventiva said it completed June 12, 2026 steps of its EIB and new debt financing. According to the company, it repaid EIB loans in full for about €62.2m and repurchased/cancelled EIB warrants for €50m (including 700,000 Tranche B warrants). It also issued Tranche A €35m convertible bonds and Tranche B €40m amortized bonds for initial gross proceeds €75m, with net proceeds €71.3m.